OI Therapy Raised BMD, Not Fracture Benefit By Andrea Surnit June 5, 2026 Conexiant Share Summary Takeaways Listen Insight Report Clinical Scorecard Quiz Top Institutions Top Thought Leaders 1 The TOPaZ trial found no significant reduction in fractures for adults with osteogenesis imperfecta treated with teriparatide and zoledronic acid. 2 Bone mineral density increased in the intervention group, but this did not correlate with a decrease in imaging-confirmed fractures. 3 Adherence to treatment was high in the intervention group at 98.3%, compared to 44.5% in the standard-care group. 4 Secondary analyses showed no statistically significant fracture benefit from teriparatide followed by zoledronic acid. 5 The study's limitations included fewer primary outcome fractures than expected, affecting the ability to detect treatment effects.
